Altimmune to Present Pemvidutide Clinical Data at Upcoming NASH-TAG Conference January 8, 2022

Rhea-AI Summary

Altimmune, Inc. (Nasdaq: ALT) announced that Dr. Scott Harris, Chief Medical Officer, will present on pemvidutide, a dual receptor agonist targeting obesity and non-alcoholic steatohepatitis (NASH). The presentations will occur at the NASH-TAG Conference from January 6-8, 2022, in Park City, Utah. Dr. Harris will deliver an oral presentation on a placebo-controlled study of pemvidutide on January 8, 2022, at 8:10 am Mountain Time. The presentation details will be available on Altimmune's website post-conference, emphasizing the company's focus on innovative treatments for obesity and liver diseases.

Positive

• Dr. Scott Harris will present pemvidutide, highlighting its potential to treat obesity and NASH.
• The presentation at the NASH-TAG Conference showcases Altimmune's commitment to developing innovative therapies.
• A placebo-controlled study indicates rigorous research backing for pemvidutide.

Negative

• None.

GAITHERSBURG, Md., Jan. 03, 2022 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that Dr. Scott Harris, Chief Medical Officer at Altimmune, will give an oral and a poster presentation on pemvidutide, the Company’s novel, investigational GLP-1/Glucagon dual receptor agonist under development for the treatment of obesity and non-alcoholic steatohepatitis (NASH), the most severe form of non-alcoholic fatty liver disease (NAFLD). The presentations will take place at the NASH-TAG Conference, which is being held January 6-8, 2022, in Park City, Utah. Details for the oral presentation are as follows:

Title:	A placebo-controlled, double-blind, first-in-human study of Pemvidutide (ALT-801), a novel GLP-1/glucagon dual receptor agonist for the treatment of NASH and obesity
Presenter:	Scott Harris, M.D., Chief Medical Officer, Altimmune, Inc.
Date/Time:	Saturday, January 8, 2022 at 8:10 am Mountain Time

A copy of Dr. Harris’ presentation and poster will be accessible on the Events section of the Altimmune website.

About Altimmune

Altimmune is a clinical stage biopharmaceutical company focused on developing treatments for obesity and liver diseases. Our pipeline includes next generation peptide therapeutics for obesity, NASH (pemvidutide), and chronic hepatitis B (HepTcell™). For more information, please visit www.altimmune.com.

Follow @Altimmune, Inc. on LinkedIn
Follow @AltimmuneInc on Twitter

Investor & Media Contacts:

Richard Eisenstadt
Chief Financial Officer
Phone: 240-654-1450
reisenstadt@altimmune.com

FAQ

What is pemvidutide and its significance for Altimmune (ALT)?

Pemvidutide is a novel GLP-1/glucagon dual receptor agonist developed by Altimmune for treating obesity and NASH, potentially offering a new therapeutic option in these areas.

When will Dr. Scott Harris present data on pemvidutide?

Dr. Scott Harris will present data on pemvidutide on January 8, 2022, at 8:10 am Mountain Time during the NASH-TAG Conference.

Where can I find the presentation on pemvidutide?

The presentation by Dr. Harris will be accessible on Altimmune's website in the Events section after the conference.

What type of study is being presented on pemvidutide?

Dr. Harris will present findings from a placebo-controlled, double-blind, first-in-human study of pemvidutide.

How does pemvidutide impact obesity and NASH treatment?

Pemvidutide's dual receptor agonist mechanism aims to effectively manage obesity and treat the severe form of fatty liver disease (NASH) by addressing underlying metabolic issues.